JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

The Prognostic Value of Systemic Inflammation Index in Breast Cancer: A Retrospective Study in Western Romania

  • 0Doctoral School in Medicine, Victor Babeș University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Journal of Clinical Medicine +

|

February 26, 2025

|

February 26, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

The systemic immune-inflammation index (SII) shows potential for predicting breast cancer outcomes and inflammatory profiles in patients. However, further research is needed before it can guide treatment decisions.

Area Of Science

  • Oncology
  • Immunology
  • Hematology

Background

  • Breast cancer is a major global health concern requiring improved prognostic tools.
  • The systemic immune-inflammation index (SII), calculated from blood tests, may offer prognostic value.
  • Individualized patient management necessitates refined tools for predicting clinical outcomes.

Purpose Of The Study

  • To evaluate the predictive capability of the systemic immune-inflammation index (SII) for clinical outcomes in breast cancer patients undergoing curative resection.
  • To determine if SII can stratify patients based on inflammatory profiles and prognostic features.

Main Methods

  • Retrospective analysis of breast cancer patients who underwent surgical intervention.
  • Calculation of preoperative SII from complete blood counts.
  • Receiver operating characteristic (ROC) curve analysis to identify optimal SII cutoff.
  • Univariate and multivariate analyses to assess associations between SII and clinicopathological factors.

Main Results

  • Elevated SII levels were significantly associated with advanced tumor stage and systemic inflammatory profiles.
  • An identified SII cutoff effectively separated patients into distinct risk groups.
  • High SII values correlated with poorer prognostic features, offering additional predictive value beyond standard markers.

Conclusions

  • The systemic immune-inflammation index (SII) shows promise in providing prognostic insights for breast cancer, particularly in stratifying patients by inflammatory status.
  • Current findings do not support using SII for tailoring breast cancer treatment strategies.
  • Further preclinical and randomized controlled trials are necessary to validate SII's predictive utility and its integration into personalized medicine.

Keywords: